Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
2
×
Tags
biotech
boston blog main
boston top stories
deals
life sciences
2
×
national blog main
national top stories
2
×
san francisco
san francisco blog main
san francisco top stories
startups
2
×
acetylon pharmaceuticals
alphabet
ambys medicines
broad institute of harvard and mit
brook byers
cell therapy
charles chu
constellation pharmaceuticals
crispr
crispr cas14
decheng capital
diagnostic
gene therapy
genentech
google
holger willenbring
infectious disease
investing
ipo
jeffrey tong
juan carlos izpisua belmonte
keith dionne
kleiner perkins
liver disease
mammoth biosciences
markus grompe
martin burke
mayfield
medical devices
What
big
2
×
today
2
×
aiming
ambys
available
based
bio
biosciences
biotech
cas
cheaper
control
crispr
deadly
deal
debuted
develop
diagnostics
diseases
expects
faster
formed
future
launch
liver
make
mammoth
medicines
new
set
startup
takeda
things
tiny
treatments
unusual
variety
what’s
Language
unset
Current search:
today
×
startups
×
photo
×
" life sciences "
×
big
×
" national top stories "
×
@xconomy.com
4 years ago
With $45M, Mammoth Bio Expects Big Things From Tiny CRISPR Cas14
@xconomy.com
5 years ago
With Big Takeda Deal at Launch, Can Ambys Keep Control of Its Future?